Aim: In this review paper we propose a method to make an early diagnosis of the Alzheimer’s Disease (AD), the most common form of neurodegenerative dementia. Background: Glymphatic System (GS) is the main means of eliminating waste substances in the central nervous system (CNS); if it does not work properly, waste substances accumulate in CNS until to cause AD. Basal Forebrain is the most important component of a much broader system of cholinergic cells distributed throughout the Central Nervous System (CNS). This structure regulates attention, learning and memory and its destruction is considered responsible for the cognitive AD alterations. The characteristics of AD patients, that interest us most, are the lack of Acetylcholine, and the Orexin excess; we think that the hypothalamus produces more Orexin to stimulate cholinergic cells, indispensable for a correct CNS functioning. We want to identify these patients by detecting the Orexin excess. Early Diagnosis Model. Of course we could take a cerebrospinal fluid sample and dose Orexin but this method is risky and painful for the patient’s health, therefore unsuitable for large numbers of patients. We propose a fairly simple method for the early diagnosis of AD: if we temporarily eliminate the Orexin excess, with Dual Orexin Receptor Antagonist (DORA), i.e. Suvorexant, we can intercept the Orexin increase and demonstrate the decrease in Acetylcholine with a Functional Magnetic Resonance or a Polysomnography, many years before the AD symptoms occur.
References
[1]
Brookmeyer, R., Gray, S. and Kawas, C. (1998) Projections of Alzheimer’s Disease in the United States and the Public Health Impact of Delaying Disease Onset. American Journal of Public Health, 88, 1337-1342. https://doi.org/10.2105/AJPH.88.9.1337
[2]
Jessen, N.A., Munk, A.S., Lundgaard, I. and Nedergaard, M. (2015) The Glymphatic System: A Beginner’s Guide. Neurochemical Research, 40, 2583-2599. https://doi.org/10.1007/s11064-015-1581-6
[3]
Plog, B.A. and Nedergaard, M. (2018) The Glymphatic System in Central Nervous System Health and Disease: Past, Present, and Future. Annual Review of Pathology, 13, 379-394. https://doi.org/10.1146/annurev-pathol-051217-111018
[4]
Louveau, A., et al. (2015) Structural and Functional Features of Central Nervous System Lymphatic Vessels. Nature, 523, 337-341. https://doi.org/10.1038/nature14432
[5]
Brown, M.K., Chan, M.T., Zimmerman, J.E., et al. (2014) Aging Induced Endoplasmic Reticulum Stress Alters Sleep and Sleep Homeostasis. Neurobiology of Aging, 35, 1431-1441. https://doi.org/10.1016/j.neurobiolaging.2013.12.005
[6]
Louveau, A., Plog, B.A., Antila, S., et al. (2017) Understanding the Functions and Relationships of the Glymphatic System and Meningeal Lymphatics. Journal of Clinical Investigation, 127, 3210-3219. https://doi.org/10.1172/JCI90603
[7]
Kobayashi, S. (2015) Choose Delicately and Reuse Adequately: The Newly Revealed Process of Autophagy. Biological and Pharmaceutical Bulletin, 38, 1098-1103. https://doi.org/10.1248/bpb.b15-00096
[8]
Glick, D., Barth, S. and Macleod, K.F. (2010) Autophagy: Cellular and Molecular Mechanisms. The Journal of Pathology, 221, 3-12. https://doi.org/10.1002/path.2697
[9]
Bandyopadhyay, U., Kaushik, S., Varticovski, L. and Cuervo, A.M. (2008) The Chaperone-Mediated Autophagy Receptor Organizes in Dynamic Protein Complexes at the Lysosomal Membrane. Molecular and Cellular Biology, 28, 5747-5763. https://doi.org/10.1128/MCB.02070-07
[10]
Boland, B., Yu, W.H., Corti, O., et al. (2018) Promoting the Clearance of Neurotoxic Proteins in Neurodegenerative Disorders of Ageing. Nature Reviews Drug Discovery, 17, 660-688. https://doi.org/10.1038/nrd.2018.109
[11]
Amiry-Moghaddam, M. and Ottersen, O.P. (2003) The Molecular Basis of Water Transport in the Brain. Nature Reviews Neuroscience, 4, 991-1001. https://doi.org/10.1038/nrn1252
[12]
Verkman, A.S. and Mitra, A.K. (2000) Structure and Function of Aquaporin Water Channels. American Journal of Physiology-Renal Physiology, 278, F13-F28. https://doi.org/10.1152/ajprenal.2000.278.1.F13
[13]
Yool, A.J. (2007) Aquaporins: Multiple Roles in the Central Nervous System. Neuroscientist, 13, 470-485. https://doi.org/10.1177/1073858407303081
[14]
Verkman, A.S., Binder, D.K., Bloch, O., et al. (2006) Three Distinct Roles of Aquaporin-4 in Brain Function Revealed by Knockout Mice. Biochimica et Biophysica Acta, 1758, 1085-1093. https://doi.org/10.1016/j.bbamem.2006.02.018
[15]
Simon, M.J., Wang, M.X., Murchison, C.F., et al. (2018) Transcriptional Network Analysis of Human Astrocytic End-Foot Genes Reveals Region-Specific Associations with Dementia Status and Tau Pathology. Scientific Reports, 8, Article No. 12389. https://doi.org/10.1038/s41598-018-30779-x
[16]
Mawuenyega, K.G., Sigurdson, W., Ovod, V., et al. (2010) Decreased Clearance of CNS Betaamyloid in Alzheimer’s Disease. Science, 330, 1774. https://doi.org/10.1126/science.1197623
[17]
Stockwell, J., Jakova, E. and Cayabyab, F.S. (2017) Adenosine A1 and A2A Receptors in the Brain: Current Research and Their Role in Neurodegeneration. Molecules, 22, pii: E676. https://doi.org/10.3390/molecules22040676
[18]
Rasmussen, M.K., Mestre, H. and Nedergaard, M. (2018) The Glymphatic Pathway in Neurological Disorders. The Lancet Neurology, 17, 1016-1024. https://doi.org/10.1016/S1474-4422(18)30318-1
[19]
Holth, J.K., Fritschi, S.K., Wang, C., et al. (2019) The Sleep-Wake Cycle Regulates Brain Interstitial Fluid Tau in Mice and CSF Tau in Humans. Science, 363, 880-884. https://doi.org/10.1126/science.aav2546
Martínez-Frailes, C., Di Lauro, C., Bianchi, C., et al. (2019) Amyloid Peptide Induced Neuroinflammation Increases the P2X7 Receptor Expression in Microglial Cells, Impacting on Its Functionality. Frontiers in Cellular Neuroscience, 13, 143. https://doi.org/10.3389/fncel.2019.00143
[22]
Xiang, C., Wang, Y., Zhang, H. and Han, F. (2017) The Role of Endoplasmic Reticulum Stress in Neurodegenerative Disease. Apoptosis, 22, 1-26. https://doi.org/10.1007/s10495-016-1296-4
[23]
Porkka-Heiskanen, T., Strecker, R.E. and McCarley, R.W. (2000) Brain Site Specificity of Extracellular Adenosine Concentration Changes during Sleep Deprivation and Spontaneous Sleep: An in Vivo Microdialysis Study. Neuroscience, 99, 507-517. https://doi.org/10.1016/S0306-4522(00)00220-7
[24]
Benington, J.H. and Heller, H.C. (1995) Restoration of Brain Energy Metabolism as the Function of Sleep. Progress in Neurobiology, 45, 347-360. https://doi.org/10.1016/0301-0082(94)00057-O
[25]
Sullan, M.J., Asken, B.M., Jaffee, M.S., DeKosky, S.T. and Bauer, R.M. (2018) Glymphaticsystem Disruption as a Mediator of Brain Trauma and Chronic Traumatic Encephalopathy. Neuroscience & Biobehavioral Reviews, 84, 316-324. https://doi.org/10.1016/j.neubiorev.2017.08.016
[26]
Xia, M., Yang, L., Sun, G., Qi, S. and Li, B. (2017) Mechanism of Depression as a Risk Factor in the Development of Alzheimer’s Disease: The Function of AQP4 and the Glymphatic System. Psychopharmacology (Berl.), 234, 365-379. https://doi.org/10.1007/s00213-016-4473-9
[27]
Zuo, C.L., Wang, C.M., Liu, J., et al. (2018) Isoflurane Anesthesia in Aged Mice and Effects of A1 Adenosine Receptors on Cognitive Impairment. CNS Neuroscience & Therapeutics, 24, 212-221. https://doi.org/10.1111/cns.12794
[28]
Kim, Y.-K., Il Nam, K. and Song, J. (2018) The Glymphatic System in Diabetes-Induced Dementia. Frontiers in Neurology, 9, 867.
[29]
Vijayan, M. and Reddy, P.H. (2016) Stroke, Vascular Dementia, and Alzheimer’s Disease: Molecular Links. Journal of Alzheimer’s Disease, 54, 427-443.
[30]
Kress, B.T., Iliff, J.J., Xia, M., et al. (2014) Impairment of Paravascular Clearance Pathways in the Aging Brain. Annals of Neurology, 76, 845-861. https://doi.org/10.1002/ana.24271
[31]
Hampel, H., Mesulam, M.M., Cuello, A.C., et al. (2019) Revisiting the Cholinergic Hypothesis in Alzheimer’s Disease: Emerging Evidence from Translational and Clinical Research. The Journal of Prevention of Alzheimer’s Disease, 6, 2-15.
[32]
Chakraborty, S., Lennon, J.C., Malkaram, S.A., et al. (2017) Serotonergic System, Cognition, and BPSD in Alzheimer’s Disease. Acta Neuropathologica Communications, 5, 8.
[33]
Kelly, S.C., He, B., Perez, S.E., Ginsberg, S.D., Mufson, E.J. and Counts, S.E. (2019) Locus Coeruleus Cellular and Molecular Pathology during the Progression of Alzheimer’s Disease. Neuroscience Letters, 704, 36-44.
[34]
Zlomuzica, A., Dere, D., Binder, S., et al. (2016) Neuronal Histamine and Cognitive Symptoms in Alzheimer’s Disease. Neuropharmacology, 106, 135-145. https://doi.org/10.1016/j.neuropharm.2015.05.007
[35]
Martorana, A., et al. (2009) Dopamine Modulates Cholinergic Cortical Excitability in Alzheimer’s Disease Patients. Neuropsychopharmacology, 34, 2323-2328. https://doi.org/10.1038/npp.2009.60
[36]
Sakurai, T., Mieda, M. and Tsujino, N. (2010) The Orexin System: Roles in Sleep/Wake Regulation. Annals of the New York Academy of Sciences, 1200, 149-161. https://doi.org/10.1111/j.1749-6632.2010.05513.x
[37]
Malkki, H. (2014) Alzheimer Disease: Increased Orexin Level Correlates with Sleep Disruption and Cognitive Decline in Alzheimer Disease. Nature Reviews Neurology, 10, 672. https://doi.org/10.1038/nrneurol.2014.209
[38]
Ferini-Strambi, L. (2014) Possible Role of Orexin in the Pathogenesis of Alzheimer Disease. JAMA Neurology, 71, 1478-1480. https://doi.org/10.1001/jamaneurol.2014.2819
[39]
Roh, J.H., et al. (2014) Potential Role of Orexin and Sleep Modulation in the Pathogenesis of Alzheimer’s Disease. Journal of Experimental Medicine, 211, 2487-2496.
[40]
Liguori, C., et al. (2014) Orexinergic System Dysregulation, Sleep Impairment, and Cognitive Decline in Alzheimer Disease. JAMA Neurology, 71, 1498-1505. https://doi.org/10.1001/jamaneurol.2014.2510
[41]
Strac, D.S., Muck-Seler, D. and Pivac, N. (2015) Neurotransmitter Measures in the Cerebrospinal Fluid of Patients with Alzheimer’s Disease: A Review. Psychiatria Danubina, 27, 14-24.
[42]
Zhang, Y., Yu, T., Liu, Y., Qian, K. and Yu, B.W. (2015) Muscarinic M1 Receptors Regulate Propofol Modulation of GABAergic Transmission in Rat Ventrolateral Preoptic Neurons. Journal of Molecular Neuroscience, 55, 830-835. https://doi.org/10.1007/s12031-014-0435-z
[43]
Luppi, P.H. and Fort, P. (2018) Neuroanatomical and Neurochemical Bases of Vigilance States. Handbook of Experimental Pharmacology, 253, 35-58.
[44]
Radnikow, G. and Feldmeyer, D. (2018) Layer- and Cell Type-Specific Modulation of Excitatory Neuronal Activity in the Neocortex. Frontiers in Neuroanatomy, 12, 1. https://doi.org/10.3389/fnana.2018.00001
[45]
Fadel, J. and Burk, J.A. (2010) Orexin/Hypocretin Modulation of the Basal Forebrain Cholinergic System: Role in Attention. Brain Research, 1314, 112-123. https://doi.org/10.1016/j.brainres.2009.08.046
[46]
Fadel, J., Pasumarthi, R. and Reznikov, L.R. (2005) Stimulation of Cortical Acetylcholine Release by Orexin A. Neuroscience, 130, 541-547. https://doi.org/10.1016/j.neuroscience.2004.09.050
[47]
Villano, I., et al. (2017) Basal Forebrain Cholinergic System and Orexin Neurons: Effects on Attention. Frontiers in Behavioral Neuroscience, 11, 10. https://doi.org/10.3389/fnbeh.2017.00010
[48]
Eggermann, E., et al. (2001) Orexins/Hypocretins Excite Basal Forebrain Cholinergic Neurones. Neuroscience, 108, 177-181. https://doi.org/10.1016/S0306-4522(01)00512-7
[49]
Calva, C.B., Fayyaz, H. and Fadel, J.R. (2018) Increased Acetylcholine and Glutamate Efflux in the Prefrontal Cortex Following Intranasal Orexin-A (Hypocretin-1). Journal of Neurochemistry, 145, 232-244. https://doi.org/10.1111/jnc.14279
[50]
Schöne, C. and Burdakov, D. (2017) Orexin/Hypocretin and Organizing Principles for a Diversity of Wake-Promoting Neurons in the Brain. Current Topics in Behavioral Neurosciences, 33, 51-74. https://doi.org/10.1007/7854_2016_45
[51]
Agostinelli, L.J., et al. (2017) Descending Projections from the Basal Forebrain to the Orexin Neurons in Mice. The Journal of Comparative Neurology, 525, 1668-1684. https://doi.org/10.1002/cne.24158
[52]
Ferrari, L.L., Park, D., Zhu, L., et al. (2018) Regulation of Lateral Hypothalamic Orexin Activity by Local GABAergic Neurons. Journal of Neuroscience, 38, 1588-1599. https://doi.org/10.1523/JNEUROSCI.1925-17.2017
[53]
Hanazawa, T. and Kamijo, Y. (2019) Effect of Suvorexant on Nocturnal Delirium in Elderly Patients with Alzheimer’s Disease: A Case-Series Study. Clinical Psychopharmacology and Neuroscience, 17, 547-550. https://doi.org/10.9758/cpn.2019.17.4.547
[54]
Saper, C.B., Chou, T.C. and Scammell, T.E. (2001) The Sleep Switch: Hypothalamic Control of Sleep and Wakefulness. Trends in Neurosciences, 24, 726-731. https://doi.org/10.1016/S0166-2236(00)02002-6
[55]
Hshieh, T.T., Fong, T.G., Marcantonio, E.R. and Inouye, S.K. (2008) Cholinergic Deficiency Hypothesis in Delirium: A Synthesis of Current Evidence. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 63, 764-772. https://doi.org/10.1093/gerona/63.7.764
[56]
Maldonado, J.R. (2013) Neuropathogenesis of Delirium: Review of Current Etiologic Theories and Common Pathways. American Journal of Geriatric Psychiatry, 21, 1190-1222. https://doi.org/10.1016/j.jagp.2013.09.005
[57]
Maldonado, J.R. (2018) Delirium Pathophysiology: An Updated Hypothesis of the Etiology of Acute Brain Failure. International Journal of Geriatric Psychiatry, 33, 1428-1457. https://doi.org/10.1002/gps.4823
[58]
Kitajima, Y., Hori, K., Konishi, K., Tani, M., et al. (2015) A Review of the Role of Anticholinergic Activity in Lewy Body Disease and Delirium. Neurodegenerative Diseases, 15, 162-167. https://doi.org/10.1159/000381522
[59]
Perry, E.K. and Perry, R.H. (1995) Acetylcholine and Hallucinations: Disease-Related Compared to Drug-Induced Alterations in Human Consciousness. Brain and Cognition, 28, 240-258. https://doi.org/10.1006/brcg.1995.1255
[60]
Atum, M., Çelik, E. and Alagöz, G. (2020) Delirium Due to the Use of Topical Cyclopentolate Hydrochloride. Ideggyogy Sz, 73, 51-52. https://doi.org/10.18071/isz.73.0051
[61]
Uslaner, J.M., Herring, W.J. and Coleman, P.J. (2020) The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts. ACS Pharmacology & Translational Science, 3, 161-168. https://doi.org/10.1021/acsptsci.9b00110
[62]
Pase, M.P., Himali, J.J., Grima, N.A., et al. (2017) Sleep Architecture and the Risk of Incident Dementia in the Community. Neurology, 89, 1244-1250. https://doi.org/10.1212/WNL.0000000000004373
[63]
Kim, D.D. (2018) Reader Response: Sleep Architecture and the Risk of Incident Dementia in the Community. Neurology, 90, 486. https://doi.org/10.1212/WNL.0000000000005049
[64]
Malek, N., Baker, M.R., Mann, C. and Greene, J. (2017) Electroencephalographic Markers in Dementia. Acta Neurologica Scandinavica, 135, 388-393. https://doi.org/10.1111/ane.12638
[65]
Musaeus, C.S., Engedal, K., Høgh, P., et al. (2018) EEG Theta Power Is an Early Marker of Cognitive Decline in Dementia Due to Alzheimer’s Disease. Journal of Alzheimer’s Disease, 64, 1359-1371. https://doi.org/10.3233/JAD-180300
[66]
Brayet, P., Petit, D., Frauscher, B., et al. (2016) Quantitative EEG of Rapid-Eye-Movement Sleep: A Marker of Amnestic Mild Cognitive Impairment. Clinical EEG and Neuroscience, 47, 134-141. https://doi.org/10.1177/1550059415603050
[67]
Liguori, C., et al. (2016) Rapid Eye Movement Sleep Disruption and Sleep Fragmentation Are Associated with Increased Orexin-A Cerebrospinal-Fluid Levels in Mild Cognitive Impairment Due to Alzheimer’s Disease. Neurobiology of Aging, 40, 120-126. https://doi.org/10.1016/j.neurobiolaging.2016.01.007
[68]
Colby-Milley, J., et al. (2015) Sleep-Wake Cycle Dysfunction in the TgCRND8 Mouse Model of Alzheimer’s Disease: From Early to Advanced Pathological Stages. PLoS ONE, 10, e0130177. https://doi.org/10.1371/journal.pone.0130177
[69]
Halassa, M.M., et al. (2009) Astrocytic Modulation of Sleep Homeostasis and Cognitive Consequences of Sleep Loss. Neuron, 61, 213-219. https://doi.org/10.1016/j.neuron.2008.11.024
[70]
Zhang, F., Zhong, R., Li, S., et al. (2019) Alteration in Sleep Architecture and Electroencephalogram as an Early Sign of Alzheimer’s Disease Preceding the Disease Pathology and Cognitive Decline. Alzheimer’s & Dementia, pii: S1552-5260(18)33621-5.
[71]
Zhou, F., Yan, X.D., Wang, C., et al. (2020) Suvorexant Ameliorates Cognitive Impairments and Pathology in APP/PS1 Transgenic Mice. Neurobiology of Aging, pii: S0197-4580(20)30053-1. https://doi.org/10.1016/j.neurobiolaging.2020.02.020
[72]
Alachkar, A., Łażewska, D., Kieć-Kononowicz, K. and Sadek, B. (2017) The Histamine H3 Receptor Antagonist E159 Reverses Memory Deficits Induced by Dizocilpine in Passive Avoidance and Novel Object Recognition Paradigm in Rats. Frontiers in Pharmacology, 8, 709. https://doi.org/10.3389/fphar.2017.00709
[73]
Cooke, J.R., Loredo, J.S., Liu, L., et al. (2006) Acetylcholinesterase Inhibitors and Sleep Architecturein Patients with Alzheimer’s Disease. Drugs Aging, 23, 503-511. https://doi.org/10.2165/00002512-200623060-00005
